212 related articles for article (PubMed ID: 32761818)
21. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
22. Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers.
Karanth L; Kanagasabai S; Abas AB
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011059. PubMed ID: 28776324
[TBL] [Abstract][Full Text] [Related]
23. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
[TBL] [Abstract][Full Text] [Related]
24. Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers.
Karanth L; Kanagasabai S; Abas AB
Cochrane Database Syst Rev; 2015 Apr; (4):CD011059. PubMed ID: 25835707
[TBL] [Abstract][Full Text] [Related]
25. Interventions for treating acute bleeding episodes in people with acquired hemophilia A.
Zeng Y; Zhou R; Duan X; Long D; Yang S
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010761. PubMed ID: 25165992
[TBL] [Abstract][Full Text] [Related]
26. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors.
Hind D; Lloyd-Jones M; Makris M; Paisley S
Cochrane Database Syst Rev; 2004; (2):CD004449. PubMed ID: 15106253
[TBL] [Abstract][Full Text] [Related]
27. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
28. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
[No Abstract] [Full Text] [Related]
29. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.
Karanth L; Barua A; Kanagasabai S; Nair NS
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD009824. PubMed ID: 30758840
[TBL] [Abstract][Full Text] [Related]
30. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.
Karanth L; Barua A; Kanagasabai S; Nair S
Cochrane Database Syst Rev; 2015 Sep; (9):CD009824. PubMed ID: 26350784
[TBL] [Abstract][Full Text] [Related]
31. Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.
Mansouritorghabeh H; Mohades ST
Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):185-190. PubMed ID: 32611303
[TBL] [Abstract][Full Text] [Related]
32. Recent improvements in the clinical treatment of coagulation factor inhibitors.
Franchini M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
[TBL] [Abstract][Full Text] [Related]
33. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
34. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
35. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
[TBL] [Abstract][Full Text] [Related]
36. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
37. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.
Karanth L; Barua A; Kanagasabai S; Nair NS
Cochrane Database Syst Rev; 2013 Apr; (4):CD009824. PubMed ID: 23633378
[TBL] [Abstract][Full Text] [Related]
38. The evolution of recombinant factor replacement for hemophilia.
Sankar AD; Weyand AC; Pipe SW
Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.
Laros-van Gorkom BA; Falaise C; Astermark J
Eur J Haematol Suppl; 2014 Aug; 76():26-38. PubMed ID: 24957105
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in the treatment of acquired hemophilia.
Stachnik JM
Ann Pharmacother; 2006 Jun; 40(6):1151-7. PubMed ID: 16735671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
